Tulmimetostat Drug Asset Due Diligence Report 2026

This Tulmimetostat Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Tulmimetostat can convert its Small molecule drug profile and EZH1 x EZH2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tulmimetostat (query alias: Tulmimetostat)
Modality / target	Small molecule drug; EZH1 x EZH2; EZH1 inhibitors, EZH2 inhibitors, Epigenetic drug
Highest global status	Phase 2
Originator	Constellation Pharmaceuticals, Inc.
Active developers	Novartis Pharmaceuticals Canada, Inc., Novartis Pharmaceuticals Australia Pty Ltd., Novartis Pharma AG

The MCP disease footprint includes Lymphoma, Solid tumor, Hormone-dependent prostate cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07206056	Phase 1/2	Recruiting	188	Primary endpoint not disclosed in English source
NCT07190300	Phase 1/2	Recruiting	181	Primary endpoint not disclosed in English source
NCT05942300	Phase 1	Recruiting	30	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Combination of tulmimetostat and PD-1 blockade for patients with advanced non–small cell lung cancer who progressed from first or second line of treatments.

Phase 1/2; n=18; evaluation: Positive. Reported fields: ORR = 20.0 % ( 6.8 - 40.6)

TulmiSTAR-02: A phase I/II open-label study of dose escalation and expansion of tulmimetostat in combination with darolutamide versus darolutamide, and tulmimetostat with abiraterone in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Phase 1/2; n=173; evaluation: Positive. Reported fields: rPFS = 71.0 % ( 49 - 85); ORR = 60.0 %

TulmiSTAR-01: A phase I/II dose optimization study of tulmimetostat in combination with luxdegalutamide versus standard of care (SOC) in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).

Phase 1/2; n=188; evaluation: Positive. Reported fields: RP2D = 100.0 mg ; RP2D = 100.0 mg

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tulmimetostat addresses Lymphoma, Solid tumor, Hormone-dependent prostate cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 3 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2024-02-06	MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders	Phase 3	US$2,900.6M stated total
2021-06-02	MorphoSys AG completed the acquisition of Constellation Pharmaceuticals, Inc..	Not disclosed	US$1,700.0M stated total
2021-06-02	Royalty Pharma to purchase royalty rights for MorphoSys' otilimab, gantenerumab, and pelabresib in diverse therapeutic applications.	Phase 3	US$1,425.0M upfront; US$150.0M milestones; US$1,575.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Application of EZH2 inhibitor and JAK inhibitor in preparation of medicine for treating tumors”. The milestone feed surfaced a patent-application signal described as “EZH2 inhibition therapies for the treatment of BRCA1-associated protein (BAP1) mutated cancers”. The milestone feed surfaced a patent-application signal described as “Therapy comprising Anti-CD19 antibody and EZH2 modulators”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO